Adage Capital Partners’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
Adage Capital Partners's AVTX Position: Q3 2026 in Review
Adage Capital Partners reduced its Avalo Therapeutics (AVTX) stake by 7.5% in Q3 2026, selling an estimated $2.37M and leaving 1,600,000 shares worth $24.5M. The position accounts for 0.03% of the portfolio, ranked #433.
Adage Capital Partners first reported a position in AVTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $32M in Q2 2026. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.
- Adage Capital Partners held 1,600,000 shares of Avalo Therapeutics worth $24.5M as of Q3 2026.
- Adage Capital Partners sold 129,000 Avalo Therapeutics shares in Q3 2026, an estimated $2.37M.
- Avalo Therapeutics made up 0.03% of Adage Capital Partners's portfolio in Q3 2026, its #433 holding.
- Adage Capital Partners first reported a position in Avalo Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Adage Capital Partners's Avalo Therapeutics position peaked at $32M in Q2 2026.
- 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.
Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.